Browsing by Author "Geredeli, Çağlayan"

Now showing 1 - 2 of 2

The Effects of Fulvestrant Treatment on Hormone Receptor-Positive Metastatic Breast Cancer
(2020) Geredeli, Çağlayan; Cihan, Sener; Arıcı, Serdar; Seçmeler, Şaban; Yasar, Nurgul; Sakin, Abdullah; Can, Orcun
Objectives: To determine fulvestrant efficacy and tolerability in Turkish patients with hormone receptor-positive metastatic breast cancer.Methods: Patients who developed metastasis while taking tamoxifen or aromatase inhibitors in the adjuvantperiod or metastatic disease at the diagnosis. Fulvestrant 500 mg was administered intramuscularly every 28days. Progression-free survival (PFS) and overall survival (OS) durations were calculated.Results: In this particular research, totally 137 patients were participated. Median PFS was 9 months (95%CI, 5.7-10.3). The 12-month PFS rate was calculated as 42%, and the 36-month PFS rate was 17%. The medianPFS was not reached in the first line use of fulvestrant in the metastatic period but 9 months and 7 months inthe second and subsequent lines respectively. Results indicated that this difference was statistically significant(p = 0.002). It was shown that patients with liver and brain metastasis had lower PFS compared patients withno liver and no brain metastasis. The estimated median OS was 38 months after fulvestrant started. The 12-month OS rate was calculated as 82.4%, and the 36-month OS rate was 50%.Conclusions: Fulvestrant contributes both PFS and OS in patients with hormone receptor-positive metastaticbreast cancer and this effect is more clear in using fulvestrant as first-line treatment.
Recurrence of Appendix Tumor: Case Report and Literature Update
(2020) Geredeli, Çağlayan; Sakin, Abdullah; Erhan, Selma Şengiz; Sönmez, Gülçin Miyase; Cihan, Sener; Arıcı, Serdar
Herein, we report a case of appendix adenocarcinoma who presented with a recurrence 8 years after the initialdiagnosis. A 54-year-old male underwent appendectomy in 2009. The pathology revealed a 1.7 cm diameterlow grade mucinous carcinoid tumor. Any additional treatment was not recommended for patient other thanappendectomy. The patient was admitted with the symptoms of ileus at 8 years after surgery and then underwentto right hemicolectomy in 2017. On histopathological examination of the specimen revealed a Goblet celladenocarcinoid tumor, arising from iliocecal valv with pericolorectal tissue invasion of 5 cm in diameter.Lymph-node metastases were found in 16 dissected lymph nodes. The patient was initiated to treat withcombined capecitabine and oxaliplatin chemotherapy. There is no clear evidence to support the superiority ofany particular chemotherapy regimen for adjuvant treatment of appendix tumors. In this regard more studiesare needed to use combined regimens.